Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: Evaluation of the impact of transient interruption of antiangiogenic treatment using ultrasound-based techniques in a murine model of hepatocellular carcinoma

Figure 2

Growth percentage delta with respect to day +5. Growth percentage delta with respect to day 5, when treatment was temporarily stopped in group 2 and definitively in group 3. Resuming treatment administration in group 2 at day +9 prevented further increase in tumor dimensions from day +9 to day +13 (+37% day +13 versus day +9, range −14, +127) whereas the definitive treatment stop in group 3 induced a tumor growth comparable to that of group 1 (placebo group) (respectively 81%, range 15–87, and 79%, range 48–127). Median values and range are reported.

Back to article page